Home » Market News » DirectorsTalk Highlights » High’ survival for many cancers diagnosed at stages 1-3
Oxford BioDynamics

High’ survival for many cancers diagnosed at stages 1-3

Adults diagnosed with stage-1 skin, prostate or breast cancer have the same chance of still being alive a year later as the general population, data from the Office for National Statistics and Public Health England suggests.

For many cancers, one-year survival rates are high if they are diagnosed in stages 1-3, but lower in stage 4.

Pancreatic cancer has the lowest rates of survival, for men and women.

The estimates are based on cancer diagnoses in England from 2012-16.

 

 

Oxford Biodynamics PLC (LON:OBD) was spun out from Oxford University in June 2007 with the aim of translating fundamental scientific advances into a commercialised platform technology and a new generation of biomarkers for cancer and other diseases including ALS.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.